Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study

BACKGROUND: Typhoid fever is a major cause of morbidity and mortality in low-income and middle-income countries. In 2017, WHO recommended the programmatic use of typhoid Vi-conjugate vaccine (TCV) in endemic settings, and Gavi, The Vaccine Alliance, has pledged support for vaccine introduction in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilcke, Joke, Antillón, Marina, Pieters, Zoë, Kuylen, Elise, Abboud, Linda, Neuzil, Kathleen M, Pollard, Andrew J, Paltiel, A David, Pitzer, Virginia E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595249/
https://www.ncbi.nlm.nih.gov/pubmed/31130329
http://dx.doi.org/10.1016/S1473-3099(18)30804-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595249/
https://www.ncbi.nlm.nih.gov/pubmed/31130329
http://dx.doi.org/10.1016/S1473-3099(18)30804-1

Ejemplares similares